Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
Commentary|Slideshows|July 24, 2024
React to CVD Risk Factors: A Preventive Cardiology Guideline Topline
Author(s)Kenneth J. Bender, PharmD, MA
Based on guidance from the American Society of Preventive Cardiology, this topline summarizes risk factors and interventions to reduce the risk of major adverse CV events.
Advertisement
Part 1 of this Guideline Topline, "Elements of Preventive Cardiology," highlights the basics of primordial and primary cardiovascular disease prevention. This short part 2 slideshow summarizes the multiple risk factors for development of atherosclerotic CVD as well as evidence for pharmacotherapeutic intervention to reduce the risk of a major adverse CV event. Both Toplines are information condensed from "Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology."
Source: German CA, Baum SJ, Ferdinand KC, et al. Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology. Am J Prevent Cardiol. 2022;12;100432. doi:10.1016/j.ajpc.2022.100432
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5